Seven Fudan-Affiliated Sci-Tech Startups Secure New Funding Rounds

With the arrival of spring, a wave of scientific and technological innovation surges. Fudan-affiliated technology enterprises are forging ahead in the capital market with the diligence of early spring, breaking through challenges and advancing steadily.

According to incomplete statistics from 【Fudan Sci-Tech Innovation】, in February 2025, a total of7 CompaniesFudan-affiliated Sci-Tech Innovation Enterprises Secure New Round of Market FinancingBiomedical, Advanced Manufacturing, SemiconductorIn multiple hard technology fields, the innovative potential continues to be unleashed.

Among these,Singular MedicalCompleted Series C financing,Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd.Completed B+ round of financing,Cloud Journey Advanced MaterialsCompleted Pre-B+ round of financing,Taisi Microelectronics,StarFive Technology,ProbioCompleted strategic financing,Tai Yi Wei XingCompleted seed round financing with cutting-edge technology from the Fudan system's deep integration of industry, academia, and research in the aerospace field.

Singular Medical, established in 2017, is a pioneer in China's self-research and production of cardiac rhythm management (CRM) medical devices, committed to creating high-end CRM medical devices made in China.

The company's product line covers Implantable Cardioverter Defibrillators (ICD), Insertable Cardiac Monitors (ICM), CSP pacing systems, and external heart failure monitoring devices. The domestically produced ICD - Anbo has broken through technical barriers and completed all clinical trial enrollments. This product is fully independently intellectual property rights, capable of automatic sensing and pacing, 40J energy charge and discharge, SVT discrimination, streamlined design, and Bluetooth telemetry. Another product, the Insertable Cardiac Monitor (ICM), also possesses full independent intellectual property rights, accurately sensing various arrhythmia ECG signals and featuring an ultra-large ECG storage capacity. As the first ICM in China, its titanium alloy body exhibits excellent biocompatibility. It not only breaks through traditional ICM technical barriers and covers home monitoring but also is the first to be equipped with Bluetooth telemetry, supporting real-time cloud transmission via mobile phones and providing more timely diagnostic and therapeutic assistance functions. This ICM has successfully completed type inspection and animal experiments, and all clinical trial enrollments and follow-ups have been finished.

Singular Medical started with the ICD, the most technically challenging product in the CRM field, and has built a complete CRM technology platform. It is growing into a supplier of full-range CRM products in China, capable of providing arrhythmia patients with comprehensive solutions from monitoring, diagnosis, and treatment to postoperative follow-up.

Singular Medical's Director and Chief Operating Officer, Liu Bo, graduated from the School of Management at Fudan University.

On February 5, 2025, Singular Medical completed its Series C financing.

Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. is a CDMO enterprise focused on Advanced Therapy Medicinal Products (ATMP), committed to providing high-quality end-to-end contract manufacturing solutions for plasmids, mRNA, LNP, exosomes, viral vectors, and cell-based drugs.

Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd.'s advanced workshops comply with cGMP standards set by the FDA, EMA, and NMPA. Strict policies and measures are implemented to protect customer intellectual property. Dedicated teams and exclusive workshops are assigned for different client projects, with rigorous document management and access control enforced to ensure project information isolation.

The core leadership team of Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. has extensive CMC and commercialization experience in the biopharmaceutical field, and has been deeply involved in the development and commercialization processes of nearly twenty marketed biologics in the United States, Europe, and China. With professional expertise and rich experience in process development and manufacturing, Jian Xin Yuan Li is committed to injecting new vitality into the development and commercialization of innovative drugs worldwide.

Yu Guoliang, Co-founder and Chairman of Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd., graduated from the School of Life Sciences at Fudan University.

On February 12, 2025, Zhejiang Jian Xin Yuan Li Pharmaceuticals Co., Ltd. completed its B+ round of financing.

Yunlu Composite Materials (Shanghai) Co., Ltd., established in 2020, is a high-tech company focusing on the research, development, and production of 3D braiding intelligent equipment and high-performance fiber composite materials. The company's headquarters and R&D center are located in Baoshan District, Shanghai. Its two production bases for intelligent equipment and composite materials are respectively situated in Yancheng City and Huai'an City, Jiangsu Province. The production bases operate under a smart factory model, with specialized workshops equipped with complete automated production lines and intelligent equipment.

The core technology of the 3D braiding intelligent equipment independently developed by Yunlu Composites has broken through the technical blockade of European and American powers. Over the past decade, it has been innovatively upgraded to the third generation, gradually realizing the import substitution and upgrading of "chokepoint" high-end intelligent equipment. All three generations of the technology are at world-leading advanced levels. The company now owns multiple independent intellectual property rights, including invention patents and utility model patents. The core technology features fully automatic, high precision, high intelligence, compound capability, one-step molding, large size, high stability, and high reliability, capable of meeting the braiding requirements of fiber preforms with different structural shapes, dimensional specifications, and performance levels.

Yunlu Composites, with three-dimensional braiding intelligent equipment technology as its core, has developed high-performance fiber composites, carbon fiber structural components, glass fiber composite pipelines, and intelligent equipment in the field of composite materials. Several key models have been successfully integrated into the aviation and aerospace fields. The company's service scope has now expanded to include aerospace vehicles, police equipment, rail transit vehicles, photovoltaic thermal field equipment, automotive parts, engineering machinery, urban pipeline networks, and sports and leisure products.

Zhu Yongfei, General Manager of Yunlu Composite Materials, graduated from the School of Management at Fudan University.

On February 6, 2025, Yunlu Composites completed its Pre-B+ round of financing.

TachyonIC (Shanghai TachyonIC Electronics Co., Ltd.), founded in Zhangjiang, Shanghai in 2019, is a leading Chinese supplier of high-performance dedicated MCU chips. The company focuses on the research and development of various chips related to IoT applications and has received strong support and investment from multiple well-known investment institutions. The company has gathered a group of top semiconductor experts and is committed to becoming a platform-based chip enterprise.

The team has the R&D capability for various system-level complex chips, with cumulative shipments of developed chips reaching billions. The company has accumulated a large number of MCU chip solutions in areas such as signal chain, touch control, power management, and BMS, covering application fields like smart consumer electronics, smart home appliances, medical health, automotive electronics, energy management, and sensing. In 2022, Taicel released the TCAExx-QDA2 series of automotive-grade intelligent touch-control chips, which are the world's first automotive-grade human-computer interaction MCU chips integrating capacitive touch and pressure sensing dual modes. In the field of automotive-grade chips produced in China, Taicel’s MCUs have entered the top tier. These differentiated chip products not only set industry benchmarks but also empower more IoT enterprises to better serve customer needs.

Xiong Haifeng, founder, chairman, and CEO of TSMC Microelectronics, graduated from the School of Management at Fudan University.

On February 10, 2025, Taisi Microelectronics completed its strategic financing.

Shanghai Seraph Technologies Co., Ltd., established in 2018, is a local high-tech enterprise with independent intellectual property rights. Based on the open-source ecosystem of RISC-V and under the leadership of a team composed of RISC-V pioneers and industry veterans, the company utilizes advanced RISC-V core customization technology and agile design methodologies. It provides world-leading products and solutions based on the RISC-V instruction set, including CPU IP, NoC IP, SoC, development boards, and more, positioning itself as a leader in China’s RISC-V software and hardware ecosystem.

Since its establishment, StarFive Technology has successively launched several RISC-V-based products: the昉·天枢 (Fang TianShu), the world's highest-performance delivered processor core; the昉·惊鸿-7110 (Fang JingHong-7110), the world’s first mass-produced high-performance application processor; and the昉·星光 2 (Fang XingGuang 2), the world’s highest-performing mass-produced single-board computer. These products cover devices, scenarios, and industries such as cloud computers, tablets, desktop/laptop computers, gateway routers, edge computing, industrial displays, smart homes, smart retail, and smart energy. In 2022, the company independently developed a highly scalable multi-core on-chip bus and LLC memory system, laying the groundwork for advanced homogeneous and heterogeneous Chiplet technology. This breakthrough completed the final steps for RISC-V implementation in data centers, achieving a closed-loop solution.

StarFive Technology, rooted in China and with a global perspective, is committed to becoming a driving force and leader in the global RISC-V technology and ecosystem. In the future, StarFive Technology will carry out comprehensive cooperation with domestic and international ecosystem partners across various aspects such as the kernel layer, system service layer, framework layer, and application layer. By leading the development of RISC-V technology, it aims to drive industry innovation, enabling RISC-V to enter more high-end application fields and create greater value for developers and customers worldwide.

Xu Tao, Co-founder and CEO of StarFive Technology, graduated from Fudan University.

On February 27, 2025, StarFive Technology completed its strategic financing.

Oribio Co., Ltd. was established at the end of 2022 as a biotechnology company focused on developing novel drugs targeting chemically modified processing enzymes. Founded by three scientists with both global academic influence and consecutive successful entrepreneurial experience, the company is committed to regulating cell states by modulating ribosomal and kinase methylation switches, aiming to develop small-molecule targeted innovative drugs for major diseases such as cancer and inflammation.

Currently, Contingent BioPharma has multiple First-in-Class drug candidates in its pipeline, with promising experimental data already obtained. Among them, the first project co-developed with XtalPi is a pan-cancer small molecule inhibitor targeting the RAS-MAPK signaling pathway, particularly RAS mutation-related cancers. This inhibitor can reverse resistance to KRAS drugs in resistant mouse models. When used in combination with KRAS drugs, it significantly outperforms existing standard therapies in inhibiting tumor growth, prolonging animal survival, and reducing mortality, showing broad market potential and application prospects. Another research project by Contingent BioPharma is a novel mechanism small molecule inhibitor for the treatment of acute pancreatitis. Preclinical data shows that it has good pharmacokinetic properties, efficacy, and a relatively ideal safety window, offering the potential for better treatment options for patients.

The mission of Ornovate Biosciences is to transform the discovery of novel regulatory nodes in protein synthesis into first-in-class precision medicines to treat some of the most challenging cancers. The company’s vision is to drive original innovation in biomedicine, benefit cancer patients worldwide, and establish itself as a global pioneer in this emerging research space.

Fei Lan, co-founder of OrbiMed, is a professor and vice dean of the Institute of Biomedical Sciences at Fudan University, and a dual-appointed professor at Zhongshan Hospital, Fudan University.

On February 10, 2025, Singular Medical completed its strategic financing.

Shanghai Taiyi Micro Space Aerospace Technology Co., Ltd. is a supplier of ultra-low orbit intelligent satellites and data applications, focusing on product development and system solution design, providing decimeter-level remote sensing data services that are highly reliable, highly accurate, highly responsive, and low-cost to global users. The company's core team has deeply participated in major national aerospace projects such as manned spaceflight, BeiDou Navigation, quantum satellites, and dark matter satellites.

Through systematic engineering design and integrated innovation, the company's team possesses three core technologies: MIO ultra-low orbit flight technology, which enhances the spatiotemporal resolution of satellite observation while reducing satellite launch costs; highly sensitive HgCdTe infrared and large dynamic range low-light technology, which captures low-light night images with greater dynamic range, sensitively detects weak signals of human activity at night, and improves spectral resolution of detection signals; and the use of industrial-grade AI chips for on-orbit visual navigation of satellites and feature recognition of non-cooperative targets, providing more efficient, intelligent, and convenient user services for massive Earth big data remote sensing. The company will also widely apply high-performance, low-cost industrial AI chips and ground-trained remote sensing large models in subsequent satellites to achieve on-orbit AI inference capabilities.

In terms of business development, Taiyi Microspace has undertaken multiple projects in sustainable development, high-precision positioning and navigation, and remote sensing applications. Additionally, the company has expanded into overseas markets through collaborations with commercial space companies, engaging in cooperative exchanges with various regions and countries. The next-generation ultra-low orbit intelligent satellite, developed based on core technology integration, is about to secure follow-up joint development orders. Moving forward, the company will continue to undertake and develop the manufacturing of high-precision intelligent satellites that contribute to human development factors. Leveraging its unique, scarce, and high-value data directly addressing economic, social, and environmental needs, the company will enhance data cost-effectiveness and user experience through systematic innovation. This effort aims to support high-quality regional economic development, dual-carbon environmental protection, social prosperity and stability, and the implementation of commercial applications.

Chen Hongyu, founder and chairman of Taiyi Weixing, is a professor at the Fudan University Institute of Optoelectronics.

On February 14, 2025, Taiyi Weixing completed its seed round of financing.